WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018107146) METHODS AND COMPOSITIONS FOR TREATMENT OF BRAF MUTANT CANCERS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/107146 International Application No.: PCT/US2017/065532
Publication Date: 14.06.2018 International Filing Date: 11.12.2017
IPC:
A61K 31/06 (2006.01) ,A61K 31/437 (2006.01) ,A61K 31/44 (2006.01) ,A61K 31/506 (2006.01) ,A61K 31/519 (2006.01) ,A61K 31/65 (2006.01)
Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER[US/US]; 1275 York Avenue New York, NY 10065, US
Inventors: LITO, Piro; US
Agent: GRIMES, Julia, Anne; US
GRIMES, Julia, Anne; US
Priority Data:
62/432,60811.12.2016US
Title (EN) METHODS AND COMPOSITIONS FOR TREATMENT OF BRAF MUTANT CANCERS
(FR) PROCÉDÉS ET COMPOSITIONS DE TRAITEMENT DE CANCERS PROVOQUÉS PAR UNE MUTATION DU GÈNE BRAF
Abstract: front page image
(EN) The present invention provides various compositions and methods useful for the treatment of BRAF-mutant tumors, such as BRAFV600E-mutant tumors. In some embodiments such methods involve administration of three active agents - a RAF inhibitor, a MEK inhibitor, and an ERK inhibitor. The present invention also provides novel intermittent dosing regimens for these three active agents that maintain maximal anti-tumor efficacy while also minimizing toxicity.
(FR) La présente invention concerne diverses compositions et divers procédés utiles pour le traitement des tumeurs provoqués par une mutation du gène BRAF, telles que les tumeurs provoqués par une mutation du gène BRAF V600E. Dans certains modes de réalisation de tels procédés impliquent l’administration de trois agents actifs - un inhibiteur de RAF, un inhibiteur de MEK, et un inhibiteur d’ERK. La présente invention concerne également de nouveaux schémas posologiques intermittents pour ces trois agents actifs qui conservent l’efficacité antitumorale maximale tout en réduisant également la toxicité.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)